| scholarly article | Q13442814 |
| P50 | author | Shih-Jen Liu | Q57420876 |
| Chia-Chyi Liu | Q40622230 | ||
| Jen-Ren Wang | Q44951100 | ||
| P2093 | author name string | Yen-Hung Chow | |
| Suh-Chin Wu | |||
| Kuang-Nan Hsiao | |||
| Charles Sia | |||
| Pele Chong | |||
| Shu-Pei Lien | |||
| Min-Shi Lee | |||
| Ai-Hsiang Chou | |||
| Meng-Shin Guo | |||
| Jui-Yuan Chang | |||
| Chia-Hsin Hsiao | |||
| Hau-Pong Tasi | |||
| P2860 | cites work | DNA vaccine constructs against enterovirus 71 elicit immune response in mice | Q21245503 |
| Identification of surface-exposed B-cell epitopes recognized by Haemophilus influenzae type b P1-specific monoclonal antibodies | Q33595670 | ||
| An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. | Q33875086 | ||
| Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. | Q33908518 | ||
| Enterovirus 71 Infection of Monocytes with Antibody-Dependent Enhancement | Q34189997 | ||
| An overview of the evolution of enterovirus 71 and its clinical and public health significance | Q34635602 | ||
| Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo | Q34692967 | ||
| Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. | Q36933517 | ||
| High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. | Q51143326 | ||
| Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides | Q79557916 | ||
| Selection and characterization of vaccine strain for Enterovirus 71 vaccine development | Q82811412 | ||
| Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection | Q84059759 | ||
| Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process | Q84443635 | ||
| A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS | Q107473800 | ||
| Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. | Q37410530 | ||
| Development of enterovirus 71 vaccines. | Q37682898 | ||
| EV71: an emerging infectious disease vaccine target in the Far East? | Q37715371 | ||
| Virus-like particles in vaccine development. | Q37798008 | ||
| Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 | ||
| Identification and characterization of a cross-neutralization epitope of Enterovirus 71. | Q39556922 | ||
| Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus | Q41261599 | ||
| Hepatitis and death following vaccination with 17D-204 yellow fever vaccine | Q43032943 | ||
| Combined peptides of human enterovirus 71 protect against virus infection in mice | Q43934303 | ||
| Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. | Q44566080 | ||
| Enterovirus 71 vaccine: when will it be available? | Q44783439 | ||
| Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge | Q45396589 | ||
| Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | Q45734536 | ||
| An apparently new enterovirus isolated from patients with disease of the central nervous system | Q46144493 | ||
| Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys | Q46801574 | ||
| Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. | Q47736273 | ||
| Surveillance of suspected poliomyelitis in Albania, 1980-1995: suggestion of increased risk of vaccine associated poliomyelitis | Q47773728 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | immunology | Q101929 |
| P304 | page(s) | 831282 | |
| P577 | publication date | 2012-09-12 | |
| P1433 | published in | Clinical and Developmental Immunology | Q15754140 |
| P1476 | title | Immunological evaluation and comparison of different EV71 vaccine candidates | |
| P478 | volume | 2012 |
| Q92223179 | An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates |
| Q38385396 | Broad spectrum assessment of the epitope fluctuation--Immunogenicity hypothesis. |
| Q36740549 | Characterization of Coxsackievirus A6- and Enterovirus 71-Associated Hand Foot and Mouth Disease in Beijing, China, from 2013 to 2015. |
| Q26771247 | Development of Novel Vaccines against Enterovirus-71 |
| Q30383172 | EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). |
| Q36496385 | EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge |
| Q38919967 | Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture |
| Q38840182 | Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine |
| Q47549540 | Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012-2016. |
| Q35053266 | Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers |
| Q30234918 | Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development |
| Q27010349 | Is a multivalent hand, foot, and mouth disease vaccine feasible? |
| Q57187881 | Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits |
| Q42254889 | Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine |
| Q37530094 | Progress on the research and development of inactivated EV71 whole-virus vaccines |
| Q34921442 | Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice |
| Q28547485 | Seroepidemiology of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus 71 Infections among Children and Adolescents in Singapore, 2008-2010 |
| Q59354284 | T Cell Immunity To Enterovirus 71 Infection In Humans And Implications For Vaccine Development |
| Q35632537 | The Epidemiological Study of Coxsackievirus A6 revealing Hand, Foot and Mouth Disease Epidemic patterns in Guangdong, China |
| Q61815829 | The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus |
| Q38225695 | Update on the development of enterovirus 71 vaccines |
Search more.